Endo encouraged on US pricing condition
Endo “continues to be encouraged” that downward pricing pressures the company has experienced in the US generic retail market “over the past few years appear to be stabilising”, president and chief executive officer Paul Campanelli has said.
You may also be interested in...
Endo sharply reduced its net loss in the first quarter, beating analysts’ earnings forecasts. While generics sales slid, revenues from its higher-margin sterile injectables unit soared.
Biocon Biologics is continuing to rack up the capital needed to close its multi-billion deal for Viatris’ global biosimilars business, with two quick equity investments from parent Biocon Limited as stipulated under its acquisition agreement.
With Teva clearing up early who will replace outgoing president and CEO Kåre Schultz, Generics Bulletin looks at five issues that await his replacement, the former Sandoz head Richard Francis.